Frontlight ResearchEarly access
Taking peopleNo phase
Multicenter Prospective Non-randomized Controlled Study of Ella Photodynamic Therapy for Cervical HSIL/CIN2
Key facts
- Who runs it
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Where
- China5 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 560 people, planned
- Started
- 29 Jan 2026
- Expected to end
- Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- ALA-PDT
- LEEP surgery
- Record updated
- 14 October 2026
Who can take part
- Age
- 25 years to 65 years
- Sex
- Women only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Female, 25-60 years, understands study procedures and consents to participate
- Colposcopy-guided cervical biopsy within 3 months showing HSIL/CIN2
- Provides written informed consent
Who cannot take part
- Use of interferon or antiviral therapy within 3 months
- Cytology showing ASC-H, HSIL, AGC, or AIS; or evidence of malignant cells on cytology/histology, or suspicion of malignancy or invasive cancer
- Colposcopy findings suggestive of invasive cancer or lesion extension to the vaginal wall
- Severe pelvic, cervical, or other gynecological inflammatory conditions identified clinically
- Undiagnosed vaginal bleeding
- Active allergic disease, porphyria, or history of allergy to the study drug or structurally similar agents
- Severe cardiovascular, neurological, psychiatric, endocrine, hepatic, or hematologic disorders; known immunodeficiency; long-term glucocorticoid or immunosuppressant use; active autoimmune disease; or other malignancies
- History of hysterectomy, cervical cancer treatment, or cervical excision/ablation within 6 months (e.g., conization, LEEP, laser)
- Any other condition deemed unsuitable for participation by the investigator
- Pregnant or breastfeeding women
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 25 and 65 years old?
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study evaluates the efficacy and safety of ALA-PDT versus LEEP in treating cervical HSIL/CIN2, aiming to demonstrate non-inferiority in clinical efficacy.
The 2 groups in the trial
- ALA-PDT GroupTreatment being tested
ALA-PDT treatment for cervical lesions 6 to 9 times
Treatment: ALA-PDT
- LEEP GroupExisting treatment, for comparison
LEEP surgery for cervical lesions
Treatment: LEEP surgery
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT07306260, who can take part
- Record updated
- 14 October 2026